Clinical Trial Detail

NCT ID NCT03991130
Title High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mina Nikanjam
Indications

renal cell carcinoma

melanoma

Therapies

Aldesleukin + Nivolumab

Age Groups: adult senior

No variant requirements are available.